Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Paul Bird, Francisco J. Blanco et al.|Annals of the Rheumatic Diseases|2016Cited by 286
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trialAlvin F. Wells, Jacob Aelion, Christopher J Edwards et al.|Lara D. Veeken|2018Cited by 101
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)Peter Nash, Jacob Aelion, Juan J. Gómez‐Reino et al.|Annals of the Rheumatic Diseases|2018Cited by 88
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patientsAlvin F. Wells, Jacob Aelion, Christopher J Edwards et al.|Lara D. Veeken|2021Cited by 12
SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical FunctionA. Wells, Jacob Aelion, Christopher J Edwards et al.|Annals of the Rheumatic Diseases|2014Cited by 3